With the burgeoning interest in groundbreaking treatments for glucose dysregulation and obesity treatment, a careful assessment of Mounjaro and the dual GIP and GLP-1 receptor agonist has become critical. While both medications function through related mechanisms – targeting glucagon-like peptide-1 and GIP receptors – key distinctions in their … Read More